Insilico Medicine launches scientific board dedicated to aging research
Insilico uses generative AI to find molecules that target the mechanisms of aging itself, not just a single disease. This new board will vet the scientific rigor of biomarkers and targets before they move into clinical trials. If you're just an occasional ChatGPT user, this won't touch your daily routine, but it's a signal of where frontier AI is headed: speeding up research into conditions that aren't really diseases in the traditional sense.
practitioners › The new "Longevity Board" oversees dual-purpose targets (aging + disease) emerging from Insilico's generative platforms, billed as an industry first.
Insilico Medicine →